Although uveitis is essentially a self-limiting disease, it is none the less necessary to institute prompt treatment to reduce the inflammatory response, relieve pain, prevent posterior or peripheral anterior sypechiae, and lower intraocular pressure in those eyes with secondary glaucoma.
Before the introduction of steroids mydriatrics were the mainstay of therapy, acting by abolishing the dilatation and constriction of the pupil and pull of the ciliary body during the movement of accommodation, thereby reducing iris and ciliary spasm and hence relieving pain and, in addition, breaking down the posterior synechiae. Steroids have been used locally as the standard form of therapy in acute and chronic uveitis since the early 1950s, their mechanism of action being to reduce the exudative inflammatory process. This is achieved to some extent by inhibiting capillary permeability, thereby decreasing the cellular and protein leakage from the circulating blood into the aqueous during inflammation. However, there have been no doubleblind studies to evaluate therapy in this field.
Topical corticosteroid therapy can cause side effects and involves such hazards as potentiation of herpes simplex and other viral diseases (Patterson and Jones, 1967) , increased susceptibility to fungal infections (Ley and Saunders, 1956) , and possible increased spread of bacterial infection (Mitsui and Hanabusa, 1955) . A specific ocular complication of local steroid therapy may be the increase in intraocular pressure that occurs in genetically predisposed individuals (Goldman, 1962; Becker and Mills, 1963; Becker, 1965) and in fact topical steroids are being used as a provocative test (Becker and Ballin, 1965) . It would seem reasonable to question the efficacy of steroids in uveitis, and this controlled doubleblind clinical trial has therefore been devised to assess the response of anterior uveitis to topical steroids.
Patients and methods
This was a double-blind trial between-patient study involving 3 treatment regimens: betamethasone phosphate (0 1%), clobetasone butyrate (0-1%), and placebo eyedrops. Patients selected for study were those presenting to the Casualty Department of St. Paul's Eye Hospital, Liverpool. Sixty patients were entered in the trial, all being cases of acute unilateral nongranulomatous anterior uveitis. Twelve did not complete for reasons stated below, and are omitted from Table 1 .
On admission of the patient to the trial a clinical history was taken and a record form was completed. Details of the patient's subjective assessment of the discomfort of the eyes, a full detailed slit-lamp 762 (Mapstone, 1968a, b, c Table 1 . They were asked to instil the drops daily into the relevant eye using 2 drops 2-hourly each day for a period of 3 weeks. In addition, guttae atropinae 1% were instilled twice daily and, when necessary, acetazolamide for secondary glaucoma.
Patients were seen at 3, 7, 14, and 21 days for reassessment and recording of findings. In those cases in which the uveitis became worse they were reviewed daily. The scoring of symptoms and signs were as in Table 2 0.--0 group.bmj.com on January 6, 2018 -Published by http://bjo.bmj.com/ Downloaded from based on the clinical signs divided the 3 groups into mild and severe cases (Table 6 ). Those cases with flare, cells, and keratic precipitates only were classed as mild uveitis, while the severe cases on initial examination had, in addition, one or more of either ptosis, exudate, or hypopyon.
Figs. 3 and 4 show the duration of uveitis in mild and severe cases in each of the 3 treatment groups.
Twelve patients did not complete the trial. Four patients were withdrawn because of worsening of the condition and they were later found to have been on placebo eyedrops. One patient was given another medication in error after starting the trial, 1 patient was withdrawn after 7 days due to de- -Elder, 1951; Duke-Elder et al., 1951; Woods, 1951; Fitzgerald, 1951; Woods, 1952a, b; Ashworth, 1954) , though there have been no controlled double-blind studies to evaluate therapy in this field. A double-blind trial was devised with the following aims: (1) to determine the place of steroids in the treatment of acute anterior uveitis by comparing steroid and placebo treated groups of patients; (2) to determine the clinical efficacy of the steroid clobetasone butyrate compared with betamethasone phosphate; (3) to confirm that the measurement of corneal temperature is a useful objective parameter for the assessment of inflammation due to anterior uveitis and to establish the correlation between this and the subjective assessment by means of a scoring system for signs and symptoms (Ashford and One of the difficulties in evaluating steroids in the treatment of uveitis is that one is dependent on the subjective assessment of the signs and symptoms resulting from the inflammatory response. However, Mapstone (1968a, b, c) and Ashford and Lamble (1974) 
